| Abstract | The lipid-lowering effect of etiroxate was studied in a double-blind cross-over trial comprising 183 patients with hyperlipoproteinaemia, most of whom had suffered myocardial infarction or exhibited confirmed coronary insufficiency. Etiroxate (40 mg daily) and placebo were administered for a period of 12 weeks each. In approximately 60% of the cases with Type IIa/IIb hyperlipoproteinaemia the cholesterol level fell by more than 10%. As regards the frequency of heart complaints, the consumption of nitroglycerine capsules, and heart rate, there were no statistically significant differences between the placebo and etiroxate phases. Thus etiroxate did not have any unfavourable cardiac side-effects in the patients of this study. No negative effects on hepatic and renal function or the peripheral blood count were observed. |
| Authors | W Schwartzkopff, H Hoffmann, J Nijssen, V Etzel |
| Journal | Medizinische Klinik
(Med Klin)
Vol. 71
Issue 38
Pg. 1555-63
(Sep 17 1976)
ISSN: 0025-8458 GERMANY, WEST |
| Vernacular Title | Wirkung von Etiroxat auf die Lipide des Blutes nach Herzinfarkt bzw. bei Angina pectoris |
| PMID | 185504
(Publication Type: Clinical Trial, Controlled Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial)
|
| Chemical References |
- Lipoproteins, LDL
- Lipoproteins, VLDL
- Placebos
- Triglycerides
- Thyroxine
|
| Topics |
- Angina Pectoris
(blood, complications)
- Blood Coagulation
(drug effects)
- Clinical Trials as Topic
- Heart
(drug effects)
- Humans
- Hypercholesterolemia
(blood, complications, drug therapy)
- Lipoproteins, LDL
(blood)
- Lipoproteins, VLDL
(blood)
- Liver
(drug effects)
- Middle Aged
- Myocardial Infarction
(blood)
- Placebos
- Thyroxine
(adverse effects, analogs & derivatives, therapeutic use)
- Triglycerides
(blood)
|
